Use of tocilizumab for rheumatoid arthritis: new evidence

Tocilizumab: a new form of biological therapy for rheumatoid arthritis

Tocilizumab for the treatment of rheumatoid arthritis.

Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody, which binds to circulating soluble IL-6 receptor and membrane-expressed IL-6 receptor, inhibiting IL-6 binding to both forms of IL-6 receptor. Several Phase III clinical trials demonstrate the clinical efficacy of tocilizumab as monotherapy or with disease-modifying anti-rheumatic drugs for adult patients with moderately to seve...

Tocilizumab for the Treatment of Rheumatoid Arthritis

Tocilizumab for the treatment of rheumatoid arthritis

Tocilizumab (TCZ) is a humanized monoclonal antibody against the IL‐6 receptor, approved in Japan, Europe and the USA for the treatment of severe rheumatoid arthritis. Several Phase III trials have shown a clinical efficacy of TCZ, such as in treatment of rheumatoid arthritis patients with no previous methotrexate failures both in combination with methotrexate and in monotherapy (the AMBITION t...

Tocilizumab: A Review in Rheumatoid Arthritis

Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor antagonist, are approved (± methotrexate) in numerous countries throughout the world, for the treatment of adults with moderate to severe active rheumatoid arthritis (RA). Extensive clinical experience has firmly established the short- and long-term efficacy and safety of tocilizumab [monotherapy or in combination...